DNA Signature Linked to Prostate Cancer Severity
By LabMedica International staff writers Posted on 08 Feb 2017 |
Image: A prostate cancer cell (Photo courtesy of ABM).
From extensive genomic analyses of localized, non-indolent prostate cancer (PrCa), researchers have succeeded to identify differences in mutational profiles between localized intermediate risk and metastatic, castrate-resistant PrCa.
The study, by a team from the Canadian Prostate Cancer Genome Network (CPC-GENE), uncovered a comprehensive set of mutations that can occur in PrCa. By cataloging these mutations, they were able to create a new signature that predicts at an early stage whether a prostate cancer tumor will become aggressive or not, allowing for more precise personalized treatment. The analyses included 200 whole-genome and 477 whole-exome sequences of localized PrCa tumors, and analyses of copy-number alterations, genomic rearrangements, and methylation.
“We hope that this research mode of testing will now go into the clinical mode in the next two to five years, and really change clinical practice for men with prostate cancer in Canada and worldwide,” said study co-leader Dr. Robert Bristow, Princess Margaret Cancer Centre. Study co-leader Dr. Paul Boutros, Ontario Institute for Cancer Research, said, “This work really gives us a map to what is going on inside a prostate cancer cell, and will become the scaffold on which precision therapy will be built.”
“Collaborations like this are key to driving scientific discoveries and ultimately delivering better care for prostate cancer patients,” said Reza Moridi, Ontario Minister of Research, Innovation and Science. Through funding of approximately CAD 20 million (~ USD 15.3 million), research of this magnitude has been made possible through a partnership between the Movember Foundation, Prostate Cancer Canada, and the Ontario Institute for Cancer Research, who released a joint statement that included: “From the tireless work of researchers to the selfless giving of donors, we applaud the efforts of everyone who has played a role in helping make CPC-GENE possible. Since its beginnings as an ambitious undertaking that was massive in scope, the goal of this project has been to greatly improve personalized care for men with prostate cancer. The findings […] represent a monumental stride towards that goal.”
The study, by Michael Fraser M et al, was published online January 9, 2017, in the journal Nature.
The study, by a team from the Canadian Prostate Cancer Genome Network (CPC-GENE), uncovered a comprehensive set of mutations that can occur in PrCa. By cataloging these mutations, they were able to create a new signature that predicts at an early stage whether a prostate cancer tumor will become aggressive or not, allowing for more precise personalized treatment. The analyses included 200 whole-genome and 477 whole-exome sequences of localized PrCa tumors, and analyses of copy-number alterations, genomic rearrangements, and methylation.
“We hope that this research mode of testing will now go into the clinical mode in the next two to five years, and really change clinical practice for men with prostate cancer in Canada and worldwide,” said study co-leader Dr. Robert Bristow, Princess Margaret Cancer Centre. Study co-leader Dr. Paul Boutros, Ontario Institute for Cancer Research, said, “This work really gives us a map to what is going on inside a prostate cancer cell, and will become the scaffold on which precision therapy will be built.”
“Collaborations like this are key to driving scientific discoveries and ultimately delivering better care for prostate cancer patients,” said Reza Moridi, Ontario Minister of Research, Innovation and Science. Through funding of approximately CAD 20 million (~ USD 15.3 million), research of this magnitude has been made possible through a partnership between the Movember Foundation, Prostate Cancer Canada, and the Ontario Institute for Cancer Research, who released a joint statement that included: “From the tireless work of researchers to the selfless giving of donors, we applaud the efforts of everyone who has played a role in helping make CPC-GENE possible. Since its beginnings as an ambitious undertaking that was massive in scope, the goal of this project has been to greatly improve personalized care for men with prostate cancer. The findings […] represent a monumental stride towards that goal.”
The study, by Michael Fraser M et al, was published online January 9, 2017, in the journal Nature.
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer